Dexmedetomidine Infusion Overdose during Anaesthesia: A Case Report

Christine Li 1 and Michael Clifford 2

1. University of Melbourne, Parkville, VIC
2. Department of Anaesthesia and Pain Management, Royal Children’s Hospital, Parkville, VIC

Correspondence:
Michael Clifford
The Royal Children's Hospital Melbourne
50 Flemington Road
Parkville, VIC 3052
Email: michael.clifford@rch.org.au

Short Title: Dexmedetomidine Overdose
Article Category: Case report

Summary
A 12 kg infant was given intravenous dexmedetomidine 0.2 µg.kg⁻¹.min⁻¹ as an adjunct for general anaesthesia. The 60-fold increase in dexmedetomidine infusion rate caused a biphasic response with initial hypertension followed by bradycardia and...
hypotension requiring inotropic support. No postoperative or long-term sequelae were noted. Dexmedetomidine infusion is usually delivered as µg.kg⁻¹.h⁻¹.

Keywords
medication error, adverse effect, pharmacokinetics, pharmacodynamics

Introduction
Dexmedetomidine is a selective alpha2-receptor antagonist used intraoperatively as an adjunct for general anaesthesia. Dexmedetomidine has the infusion regimen of µg.kg⁻¹.h⁻¹, rather than the common infusion regimen of µg.kg⁻¹.min⁻¹. This produces potential for error, where previous overdoses have been reported ¹,². There are few reports describing dexmedetomidine infusions administered at 60-times the intended rate for an extended period of time in infants.

Case Report
A 12 kg, 23-month-old male, ASA III, with a history of tuberous sclerosis presented for neurosurgery and magnetic resonance imaging (MRI). A review of systems revealed mild left hemiplegia, cardiac tumours, cystic kidney disease, renal angiomyolipomas and retinal hamartomas. The infant presented in a calm, non-agitated state, with heart rate (HR) 109 bpm and blood pressure (BP) 113/79 mmHg. Dexmedetomidine 12 µg was administered as premedication.

The infant underwent sevoflurane induction with atracurium 6 mg, remifentanil 10 µg and dexamethasone 8 mg. The procedure involved two stages; MRI followed by surgery. Anaesthesia during MRI was maintained with sevoflurane. Anaesthesia during the operative stage initially involved remifentanil 0.2 µg kg⁻¹.min⁻¹ and dexmedetomidine 0.2 µg.kg⁻¹.min⁻¹. The incorrect rate of dexmedetomidine infusion was an unnoticed pump programming error, where the intended infusion rate was 2.0 µg.kg⁻¹.h⁻¹.

The infant was initially hypertensive at 130/80 mmHg. After 100 minutes of dexmedetomidine infusion, a decline in HR and BP were noted (Figure 1a). Dexmedetomidine was decreased to 0.1 µg.kg⁻¹.min⁻¹. It was a further 20 minutes
before the dexmedetomidine infusion was ceased and anaesthesia continued with isoflurane. Epinephrine 0.05 µg.kg\(^{-1}\).min\(^{-1}\) was commenced and propofol 40 mg administered. Although the infant’s HR increased to 110 bpm, BP persisted at 80/30 mmHg. Remifentanil was reduced to 0.1 µg.kg\(^{-1}\).min\(^{-1}\) and norepinephrine 0.05 µg.kg\(^{-1}\).min\(^{-1}\) was commenced. Additional analgesics, paracetamol 180 mg and fentanyl 20 µg were administered. A total of 750 mL of balanced crystalloid was delivered intraoperatively.

The remainder of the 6.5-hour operation was unremarkable. The infant was stable with HR 90 bpm, BP 100/40 mmHg and spontaneously ventilating with SpO\(_2\) 95% on room air upon conclusion of the procedure. The infant did not suffer further sequelae related to the dexmedetomidine overdose in the recovery and postoperative periods.

Discussion
We report a case of dexmedetomidine infusion administered at 60-times the intended rate for 120 minutes in a 23-month-old infant, resulting in bradycardia and hypotension. Medication errors involving infusions are invariably due to errors with dose or rate. Correctly programmed drug libraries are critical tools in preventing dose and rate-related errors. Following this incident, the pump manufacturer was notified and a widespread recall of infusion pumps was conducted for reprogramming. Besides the integration of preprogramed infusion pumps, there was no formally established system to prevent dose-related medication errors at the time of the incident. Institutional changes are critical in improving medication safety. This may involve integration of protocols that require manual double-checking by anaesthetic technicians and nurses. Increasing the number of steps in the checking process reduces the chance of a medication error.

Dexmedetomidine results in competing actions. Direct peripheral alpha-2B adrenoceptor activation initially produces sympathomimetic effects. After dexmedetomidine crosses the blood brain barrier, central alpha-2A adrenoceptors cause sympatholysis. This results in the delayed onset of overriding central sympatholytic
effects. We found decreasing HR and BP at high concentrations of dexmedetomidine. This differs from previously reported dexmedetomidine overdose at 60-times the intended rate in a 21-month-old infant, where cardiovascular stability was maintained without the requirement for intervention.

Simulation was used to predict dexmedetomidine concentrations and haemodynamic response using estimates of mean arterial pressure (MAP). Observed BP changes (Figure 1a) with dexmedetomidine infusion initially followed simulation predictions (Figure 1b). Observations deviate from predicted MAP after 70 minutes, when a decrease in BP and HR were noted. The cause of these decreases is unknown. Contributing factors may include other vasoactive drugs administered, myocardial compromise due to prolonged hypertension, or direct myocardial effects due to high concentrations of dexmedetomidine.

This case report illustrates unexpected medication error due to incorrectly preprogramed infusion pumps. The 60-fold increase in dexmedetomidine infusion rate for 120 minutes resulted in bradycardia and hypotension. This deviated from previously reported dexmedetomidine overdose in a 21-month-old infant and simulated predictions of MAP.

**Learning Points**

1. Medication errors are often preventable.
2. Manual double-checking of preprogramed drug infusions is recommended to prevent dosing errors.
3. Practitioners facing dexmedetomidine overdose should be prepared to manage hypertension followed by delayed bradycardia and hypotension.

**Disclosures**

**Ethics Approval**

Not required.

**Conflicts of Interest**

None.
References


Figure Legend

Figure 1a. Changes in heart rate and blood pressure with anaesthetic regime
Figure 1a. Changes in heart rate and blood pressure with anaesthetic regime

Figure 1b. Dexmedetomidine concentration and mean arterial pressure using pharmacokinetic pharmacodynamic simulation $^{2,3}$

Author/s:
Li, C; Clifford, M

Title:
Dexmedetomidine infusion overdose during anesthesia: A case report

Date:
2020-01-27

Citation:

Persistent Link:
http://hdl.handle.net/11343/275299